HCPCS M1414: Documentation of Medical Reason for Not Performing PD-L1 Test - OpenPayer

Summary & Overview

HCPCS M1414: Documentation of Medical Reason for Not Performing PD-L1 Test

HCPCS Level II code M1414 captures documentation that a PD-L1 biomarker expression test was not performed for medical reasons before starting first-line immune checkpoint inhibitor therapy. The code formalizes situations where clinicians document that testing would unacceptably delay treatment or is contraindicated, enabling consistent reporting of medically necessary deviations from biomarker-guided therapy initiation. Nationally, this matters as immunotherapy decisions increasingly rely on biomarker data; a standardized code supports clinical documentation, utilization review, and quality measurement across payers.

Key payers in scope include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise outline of the clinical context for using the code, typical sites of service where the code applies, and what to expect in payer coverage conversations. The publication summarizes benchmarks and policy-relevant issues related to capturing exceptions to PD-L1 testing, explains how the code is used in clinical workflows, and highlights implications for claims processing and quality measurement. Data not available in the input for associated taxonomies, ICD-10 diagnoses, related codes, and payer-specific coverage policies is noted as unavailable where relevant.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareM1414HCPCS Level IIPD-L1 testingimmune checkpoint inhibitoroncologyclinical documentationbiomarker exceptionhospital inpatientoutpatient oncology

Billing Code Overview

HCPCS Level II code M1414 documents the medical reason(s) for not performing the PD-L1 biomarker expression test prior to initiating first-line immune checkpoint inhibitor therapy. The code is used when a clinician records that testing was omitted for medical reasons (for example, the patient is in an urgent or emergent situation where delaying treatment would jeopardize the patient's health, or other documented medical contraindications).

Service type: Documentation of a medical exception to guideline-recommended biomarker testing prior to first-line immune checkpoint inhibitor therapy

Typical site of service: Hospital inpatient or outpatient oncology setting, including emergency or urgent-care situations where immediate initiation of immune checkpoint inhibitor treatment is required.

Clinical & Coding Specifications

Clinical Context

A patient with newly diagnosed advanced non–small cell lung cancer is evaluated in oncology clinic. The treating medical oncologist determines that first-line immune checkpoint inhibitor therapy cannot be delayed pending PD-L1 biomarker testing because the patient is acutely symptomatic with rapidly progressive respiratory failure and requires urgent initiation of systemic therapy to prevent imminent clinical deterioration. Documentation in the medical record states the specific medical reason for not obtaining PD-L1 testing prior to therapy initiation (e.g., urgent need for therapy, hemodynamic instability, inability to obtain adequate tumor tissue in a timely manner, or contraindication to biopsy). The clinical workflow includes: initial assessment, multidisciplinary discussion (medical oncology, thoracic surgery/interventional radiology, pathology), documentation of the medical rationale for bypassing PD-L1 testing in the chart, initiation of immunotherapy with contemporaneous plans to obtain tumor testing when feasible, and follow-up documentation of any subsequent PD-L1 testing results. Typical sites of service include hospital inpatient units, emergency departments, and oncology infusion centers when urgent treatment is administered.

Coding Specifications

Modifier	Description	When to Use
`22`	Increased procedural services	Use when documentation supports substantially greater physician work due to complexity of documenting why PD-L1 testing was not performed prior to urgent therapy.

HCPCS Level II M1251: Proxy-Completed Patient Health Survey

HCPCS-M1378-COLORECTAL-SURVEILLANCE-INTERVAL-JUSTIFICATION

HCPCS M1378: Documentation of Medical Reason for Not Recommending 10-Year Follow-Up

HCPCS-M1270-NOT-ON-KIDNEY-TRANSPLANT-WAITLIST-STATUS

HCPCS Level II M1270: Not on Kidney or Kidney-Pancreas Transplant Waitlist

HCPCS-M1343-PAM-LEVEL-4-OR-INVALID-RESPONSE-ASSESSMENT

HCPCS M1343: Assessment for PAM Level 4 or Invalid PAM Responses

HCPCS-M1280-BILATERAL-MASTECTOMY-HISTORY

HCPCS Level II M1280: Bilateral Mastectomy or History of Bilateral Mastectomy

HCPCS-M1147-ONGOING-CARE-DISCONTINUED-DUE-TO-HOSPITALIZATION-OR-SURGERY

HCPCS M1147: Ongoing Care Discontinued Due to Hospitalization or Surgery

HCPCS-M1415-NO-POSITIVE-PD-L1-BEFORE-FIRST-LINE-IMMUNOTHERAPY

HCPCS Level II M1415: No Positive PD-L1 Before First-Line Immunotherapy

HCPCS-M1193-MMR-MSI-PATHOLOGY-REPORT-RECOMMENDATION-TESTING

HCPCS M1193: Surgical Pathology Report for MMR/MSI Testing

HCPCS-M1449-SCHIZOPHRENIA-PSYCHOTIC-DISORDER-DIAGNOSIS

HCPCS M1449: Active Diagnosis of Schizophrenia or Psychotic Disorder

HCPCS-M1498-DIAGNOSTIC-RADIOLOGY-MIPS-VALUE-PATHWAY

HCPCS M1498: Diagnostic Radiology MIPS Value Pathway

Showing 1–10 of 356

Taxonomy Code	Specialty	Notes
`207RC0000X`	Medical Oncology	Primary specialty documenting decision to initiate immune checkpoint inhibitor therapy without prior PD-L1 testing.
`2084P0800X`	Hematology & Oncology	Clinicians who commonly manage systemic therapy decisions and document rationale.
`207L00000X`	Pulmonary Disease	Specialists involved when lung biopsy or urgent respiratory management influences testing decisions.
`2086S0105X`	Surgical Oncology	Surgeons who perform tissue acquisition and document intraoperative reasons for not obtaining PD-L1 sample.
`363A00000X`	Pathology	Pathologists who may document sample adequacy and reasons testing was not performed prior to therapy.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C34.90`	Malignant neoplasm of unspecified part of unspecified bronchus or lung, unspecified	Common primary diagnosis for which PD-L1 testing guides first-line immunotherapy decisions; urgent progression may prompt immediate therapy without prior testing.
`C34.10`	Malignant neoplasm of upper lobe, right bronchus or lung	Specific lung cancer site where PD-L1 testing is typically obtained but may be bypassed for urgent treatment.
`C78.00`	Secondary malignant neoplasm of unspecified lung	Metastatic involvement prompting systemic therapy where PD-L1 testing could be informative but may be deferred.
`J96.00`	Acute respiratory failure, unspecified whether with hypoxia or hypercapnia	Acute respiratory compromise that can create an emergent need to start therapy and justify not delaying for PD-L1 testing.
`R65.21`	Severe sepsis with septic shock	Critical illness that may preclude timely tissue acquisition and testing prior to initiating life‑saving therapy.
`Z92.89`	Personal history of other specified medical treatment	Administrative code used to document prior therapies or contraindications relevant to planning immunotherapy and testing decisions.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`44180`	Biopsy, intra-abdominal, percutaneous needle	May be performed before PD-L1 testing when tissue is required; absence or failure of this procedure can justify documentation for not performing PD-L1 testing prior to therapy.
`32405`	Biopsy, lung; open (thoracotomy or thoracoscopy)	Surgical tissue acquisition option; documentation that this could not be performed for medical reasons supports use of the HCPCS rationale code.
`32498`	Biopsy, lung; percutaneous needle	Minimally invasive tissue sampling commonly used to obtain material for PD-L1 testing; inability to safely perform this may be documented.
`88305`	Level III surgical pathology, gross and microscopic examination	Pathology processing and interpretation when tissue is obtained; absence of pathology results prior to therapy should be documented if testing was not done.
`81599`	Unlisted multianalyte genetic test	Used for specialized tumor biomarker assays when applicable; referenced when standard PD-L1 testing is not performed and alternative testing is sought.

OpenPayer